Achillion Pharmaceuticals, Inc. (ACHN) announced the receipt of a fast track designation from the U.S. Food and Drug Administration, or FDA, for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C, or HCV. ACH-3102 is a pan-genotypic second-generation NS5A inhibitor against HCV that was discovered by Achillion and is currently being evaluated in a Phase 1 clinical trial.
Fast Track designation was requested for ACH-3102 for its potential to provide - improved safety as compared to the current standard of care, potential for development in a once daily interferon-free fixed dose combination, potent antiviral activity in vitro against HCV genotypes 1 through 6 and low potential for drug-drug interactions and therefore greater potential to treat HCV patients with comorbidities, co-infected with HIV, or pre- or post-liver transplantation.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.